Human medicines European public assessment report (EPAR): Zerbaxa, ceftolozane,tazobactam, Date of authorisation: 18/09/2015, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 12 June 2025 - 14:45

Human medicines European public assessment report (EPAR): Zerbaxa, ceftolozane,tazobactam, Date of authorisation: 18/09/2015, Revision: 17, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Doptelet, avatrombopag maleate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders;Haematology-Hemostaseology,

Submitted by Anonymous (not verified) on 12 June 2025 - 14:38

Opinion/decision on a Paediatric investigation plan (PIP): Doptelet, avatrombopag maleate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders;Haematology-Hemostaseology, PIP number: P/0137/2024

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 12 June 2025 - 14:09

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 4, Status: Authorised

Eighth European Medicines Agency (EMA) and EFPIA bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 8 July 2025, 15:00 (CEST) to 8 July 2025, 17:00 (CEST)

Submitted by Anonymous (not verified) on 12 June 2025 - 13:30

Eighth European Medicines Agency (EMA) and EFPIA bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 8 July 2025, 15:00 (CEST) to 8 July 2025, 17:00 (CEST)

Opinion/decision on a Paediatric investigation plan (PIP): Jyseleca, filgotinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0119/2024

Submitted by Anonymous (not verified) on 12 June 2025 - 13:06

Opinion/decision on a Paediatric investigation plan (PIP): Jyseleca, filgotinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0119/2024

Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date of authorisation: 09/11/2017, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 12 June 2025 - 11:07

Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date of authorisation: 09/11/2017, Revision: 10, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness